{"id":15196,"date":"2018-03-07T17:00:34","date_gmt":"2018-03-07T17:00:34","guid":{"rendered":"https:\/\/celonpharma.com\/?p=15196"},"modified":"2018-03-07T17:00:34","modified_gmt":"2018-03-07T17:00:34","slug":"clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants","status":"publish","type":"post","link":"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/","title":{"rendered":"Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants"},"content":{"rendered":"

Celon Pharma S.A. has finalised another part of the phase I clinical trial for its esketamine-based drug. The centre conducting the study confirmed that the course of this part of the trial is in accordance with the assumptions defined in the clinical protocol.<\/p>\n

\n

Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:<\/strong>\u00a0Participants received different doses of the drug, in inhalation sequences, determined based on an analysis of safety results and pharmacokinetic parameters obtained in the first part of the phase I trial. In the next part, we will assess the safety of repeated administration of fixed doses of the drug to participants, in specific inhalation sequences, as compared to placebo. The course of the trial reflects the assumptions we have adopted in the field of patient safety in full, as defined in the clinical protocol. In accordance with the adopted time schedule, we should finalise the entire phase I in May 2018.<\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"

Celon Pharma S.A. has finalised another part of the phase I clinical trial for its esketamine-based drug. The centre conducting the study confirmed that the course of this part of the trial is in accordance with the assumptions defined in the clinical protocol. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:\u00a0Participants receivedRead more »<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[],"class_list":["post-15196","post","type-post","status-publish","format-standard","hentry","category-general-en"],"acf":[],"yoast_head":"\nClinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants - CelonGROUP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants - CelonGROUP\" \/>\n<meta property=\"og:description\" content=\"Celon Pharma S.A. has finalised another part of the phase I clinical trial for its esketamine-based drug. The centre conducting the study confirmed that the course of this part of the trial is in accordance with the assumptions defined in the clinical protocol. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:\u00a0Participants receivedRead more »\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/\" \/>\n<meta property=\"og:site_name\" content=\"CelonGROUP\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-07T17:00:34+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/\",\"url\":\"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/\",\"name\":\"Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants - CelonGROUP\",\"isPartOf\":{\"@id\":\"https:\/\/celon.group\/en\/#website\"},\"datePublished\":\"2018-03-07T17:00:34+00:00\",\"author\":{\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\"},\"breadcrumb\":{\"@id\":\"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/celon.group\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/celon.group\/en\/#website\",\"url\":\"https:\/\/celon.group\/en\/\",\"name\":\"CelonGROUP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/celon.group\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\",\"name\":\"Ma\u0142gorzata Siewierska\",\"url\":\"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants - CelonGROUP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/","og_locale":"en_US","og_type":"article","og_title":"Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants - CelonGROUP","og_description":"Celon Pharma S.A. has finalised another part of the phase I clinical trial for its esketamine-based drug. The centre conducting the study confirmed that the course of this part of the trial is in accordance with the assumptions defined in the clinical protocol. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:\u00a0Participants receivedRead more »","og_url":"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/","og_site_name":"CelonGROUP","article_published_time":"2018-03-07T17:00:34+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/","url":"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/","name":"Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants - CelonGROUP","isPartOf":{"@id":"https:\/\/celon.group\/en\/#website"},"datePublished":"2018-03-07T17:00:34+00:00","author":{"@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf"},"breadcrumb":{"@id":"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celon.group\/en\/2018\/03\/07\/clinical-trial-of-an-esketamine-based-drug-is-right-on-schedule-and-in-accordance-with-assumptions-regarding-safety-of-participants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celon.group\/en\/"},{"@type":"ListItem","position":2,"name":"Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants"}]},{"@type":"WebSite","@id":"https:\/\/celon.group\/en\/#website","url":"https:\/\/celon.group\/en\/","name":"CelonGROUP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celon.group\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf","name":"Ma\u0142gorzata Siewierska","url":"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/"}]}},"_links":{"self":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/15196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/comments?post=15196"}],"version-history":[{"count":0,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/15196\/revisions"}],"wp:attachment":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/media?parent=15196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/categories?post=15196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/tags?post=15196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}